Katrina M. Pollock

Imperial College London - Department of Infectious Disease

SCHOLARLY PAPERS

7

DOWNLOADS
Rank 540

SSRN RANKINGS

Top 540

in Total Papers Downloads

65,712

SSRN CITATIONS

3

CROSSREF CITATIONS

2

Scholarly Papers (7)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, Federal University of São Paulo (UNIFESP), University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand, Stellenbosch University - Family Centre for Research with Ubuntu, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - Vaccines and Infectious Diseases Analytics Research Unit, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, GSK plc, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, University of Liverpool - School of Tropical Medicine, University of Bristol - Bristol Vaccine Centre, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group and Independent
Downloads 52,358 (50)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge - Department of Medicine, University of Oxford - Big Data Institute, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, GSK plc, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Liverpool - School of Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Bristol - Bristol Vaccine Centre, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, St George’s University London - St George’s Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, Genomics England, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Independent and Independent
Downloads 10,971 (911)
Citation 26

Abstract:

Loading...

3.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Number of pages: 34 Posted: 16 Jun 2021
Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, NIHR UCLH Clinical Research Facility, Imperial College London, NIHR Imperial Clinical Research Facility, University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London, Imperial College London, University College London Hospitals NHS Foundation Trust - Department of Clinical Virology, University College London, Government of the United Kingdom - Chelsea and Westminster Hospital NHS Foundation Trust, Imperial College London, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, NIHR Imperial Clinical Research Facility, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, St George’s University London - St George’s Vaccine Institute, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 1,531 (23,309)

Abstract:

Loading...

4.

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Number of pages: 39 Posted: 19 Apr 2021
University of Oxford - Peter Medawar Building for Pathogen Research, GSK plc, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, NIHR Imperial Clinical Research Facility, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University College London - Department of Infection, University of Oxford - The Jenner Institute, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Imperial College London - Department of Infectious Disease, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Oxford Vaccine Group, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, NIHR Guy's and St Thomas' Biomedical Research Centre, Imperial College London - Department of Infectious Disease, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Oxford Vaccine Group, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, University of Oxford - Peter Medawar Building for Pathogen Research, Oxford University Hospitals NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, University of Oxford - Department of Paediatrics, University of Oxford - Peter Medawar Building for Pathogen Research, Guy's and St Thomas' NHS Foundation Trust - Department of Infection, Imperial College London - Department of Infectious Disease, University of Oxford - The Jenner Institute, University of Oxford - Chinese Academy of Medical Science Oxford Institute (COI), University of Oxford - Oxford Vaccine Group, Imperial College London - Section of Virology, Guy's and St Thomas' NHS Foundation Trust - Harrison Wing, University of Oxford - The Jenner Institute and Independent
Downloads 657 (75,943)
Citation 2

Abstract:

Loading...

5.

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)

Number of pages: 40 Posted: 21 Sep 2022
Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, Imperial College London - Department of Metabolism, Digestion and Reproduction, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - IBD Pharmacogenetics Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, affiliation not provided to SSRN, Newcastle University, Government of the United Kingdom - Department of Gastroenterology, Barts Health NHS Trust - Department of Gastroenterology, NHS Lothian - Department of Gastroenterology, Imperial College London - Department of Immunology and Inflammation, St Marks Hospital and Academic Institute - Department of Gastroenterology, Imperial College London, Imperial College London - Department of Infectious Disease, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter - Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Royal Devon and Exeter NHS Foundation Trust - Department of Gastroenterology and Imperial College London - Department of Metabolism, Digestion and Reproduction
Downloads 85 (543,939)

Abstract:

Loading...

SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, thiopurine, azathioprine, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, mRNA1273, breakthrough infection, Omicron, BA.4/5

6.

Characterisation of Rare Spontaneous HIV Viral Controllers Attending a National UK Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays

Number of pages: 26 Posted: 12 Jul 2022
Imperial College London - Section of Virology, UK Health Security Agency - Virus Reference Department, UK Health Security Agency - Virus Reference Department, Imperial College London - National Centre for Human Retrovirology, UK Health Security Agency - Virus Reference Department, UK Health Security Agency - Virus Reference Department, Imperial College London - Department of Infectious Disease, Imperial College London - Section of Virology, Imperial College London - Section of Virology, Imperial College London - Department of Infectious Disease, Imperial College London - Imperial College Healthcare NHS Trust, Imperial College London - Section of Virology, Imperial College London - Section of Virology, Imperial College London - Section of Infectious Diseases and Immunity, Imperial College London - Section of Infectious Diseases and Immunity, Imperial College London - Section of Virology and Imperial College London - Section of Virology
Downloads 66 (627,176)

Abstract:

Loading...

HIV elite control, HIV indeterminate results, HIV diagnosis

7.

COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Number of pages: 33 Posted: 27 Sep 2022
University College London - MRC Clinical Trials Unit, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, Imperial College London - Department of Infectious Disease, University College London - MRC Clinical Trials Unit, St George’s University London - St George’s Vaccine Institute, Government of the United Kingdom - Department of HIV/GUM, Government of the United Kingdom - Department of HIV/GUM, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, St George’s University London - St George’s Vaccine Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Imperial College London - Section of Virology, St George’s University London - St George’s Vaccine Institute, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, NIHR UCLH Clinical Research Facility, Imperial College London - Department of Infectious Disease, Chelsea and Westminster Hospital NHS FT, Imperial College London - Department of Infectious Disease, NIHR Imperial Clinical Research Facility - NIHR Imperial Biomedical Research Centre, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton - NIHR Southampton Biomedical Research Centre, University College London - Comprehensive Biomedical Research Centre, University of Surrey - Surrey Clinical Research Centre, Imperial College London - Department of Infectious Disease, University of Surrey - Surrey Clinical Research Centre, University College London - Comprehensive Biomedical Research Centre, University College London - MRC Clinical Trials Unit, University College London - MRC Clinical Trials Unit and Imperial College London - Department of Infectious Disease
Downloads 44 (755,083)

Abstract:

Loading...

SARS-CoV-2, vaccination, self-amplifying RNA, saRNA, immune response